Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 37Neoplasms, Plasma Cell 11Recurrence 6Lymphoma, Mantle-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Rectal Neoplasms 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasm Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Liver Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1Leukemia 1Hypoxia 1

Interventions

TH 302 2Radiotherapy 2pomalidomide 1pimonidazole 1inositol trispyrophosphate 1fluoroazomycin arabinoside 1Thoracotomy 1Thoracic Surgery, Video-Assisted 1Propofol 1Positron Emission Tomography Computed Tomography 1Nimorazole 1Metformin 1Letrozole 1Ipilimumab 1Hydroxychloroquine 1Drug Therapy 1Diagnostic Imaging 1Dexamethasone 1Circulating Tumor DNA 1Bortezomib 1AQ4N 14-methylbenzenesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hypoxia × Bortezomib × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡